OPKO Health, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $65.4 million (+15.9% year over year) and diluted EPS of -$0.07. It usually reports 27–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 27–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
65
+15.9%
|
-54
-347.5%
|
-0.07
-333.3%
|
|
Jul 27, 2026
27 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
164
+4.3%
|
-8
+94.3%
|
-0.01
+94.7%
|
|
Apr 28, 2026
28 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
124
-17.2%
|
-55
+18.9%
|
-0.07
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
148
-19.2%
|
-31
-322.8%
|
-0.04
-500.0%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
56
-67.5%
|
22
-13.1%
|
0.03
+0.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
157
-13.9%
|
-148
-1340.5%
|
-0.19
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
150
-13.7%
|
-68
+17.4%
|
—
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
184
+1.0%
|
14
+121.1%
|
0.01
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OPK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- Accelerated filer
- SEC CIK
- 944809
- Former names
- EXEGENICS INC (until Jun 13, 2007); eXegenics Inc (until Jun 13, 2007); CYTOCLONAL PHARMACEUTICS INC /DE (until Jun 4, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.